<div id="readability-page-1"><p><span>OptimizeRx (NASDAQ:OPRX - Get Free Report)</span> was upgraded by investment analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report issued to clients and investors on Sunday.</p><p>Several other equities analysts have also recently issued reports on the company. UBS Group  set a $23.00 target price on OptimizeRx in a research note on Friday, October 10th. Citizens Jmp raised their target price on shares of OptimizeRx from $23.00 to $24.00 and gave the company a &#34;market outperform&#34; rating in a research note on Friday, November 7th. Zacks Research upgraded shares of OptimizeRx from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday, November 14th. Citigroup  restated an &#34;outperform&#34; rating on shares of OptimizeRx in a research note on Friday, October 10th. Finally, Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of OptimizeRx in a research report on Monday, December 8th. One investment analyst  has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $16.88.</p><p><b>View Our Latest Analysis on OPRX</b></p><h2>OptimizeRx Stock Down 4.8%</h2><p>OptimizeRx stock opened at $13.36 on Friday. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $249.03 million, a P/E ratio of 33.40 and a beta of 1.10. OptimizeRx has a twelve month low of $3.99 and a twelve month high of $22.25. The firm has a 50 day moving average price of $17.04 and a 200-day moving average price of $15.93. </p><p>OptimizeRx (NASDAQ:OPRX - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.03 by $0.17. The company had revenue of $26.07 million during the quarter, compared to analysts' expectations of $23.83 million. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%.  As a group, equities analysts predict that  OptimizeRx will post -0.33 EPS for the current year. </p><h2>Insider Activity at OptimizeRx</h2><p>In related news, CEO Stephen L. Silvestro sold 1,620 shares of the company's stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the completion of the sale, the chief executive officer directly owned 188,916 shares in the company, valued at $3,542,175. This represents a 0.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own  5.60% of the company's stock. </p><h2>Hedge Funds Weigh In On OptimizeRx</h2><p>A number of large investors have recently made changes to their positions in OPRX. Charles Schwab Investment Management Inc. boosted its stake in  OptimizeRx by 30.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,228 shares of the company's stock worth $470,000 after purchasing an additional 12,676 shares in the last quarter.  Invesco Ltd. acquired a new stake in  OptimizeRx in the 1st quarter valued at about $2,542,000.  Virtu Financial LLC acquired a new stake in  OptimizeRx during the first quarter worth about $112,000.  Nuveen LLC purchased a new position in shares of  OptimizeRx during the 1st quarter worth $455,000.  Finally, Russell Investments Group Ltd. increased its holdings in  OptimizeRx by 25,355.6% in the 1st quarter. Russell Investments Group Ltd. now owns 45,820 shares of the company's stock valued at $397,000 after purchasing an additional 45,640 shares during the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds. </p><h2>About OptimizeRx</h2> (Get Free Report)<p>OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than OptimizeRx</li><li>What Are the FAANG Stocks and Are They Good Investments?</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>What is the S&amp;P/TSX Index?</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>3 Healthcare Dividend Stocks to Buy</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1BSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1BSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in OptimizeRx Right Now?</h2><p>Before you consider OptimizeRx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.</p><p>While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OPRX

<p>Wall Street Zen upgraded OptimizeRx (NASDAQ: OPRX) from a "buy" rating to a "strong-buy" rating. Other analysts have also issued positive ratings, with UBS Group and Citizens Jmp setting target prices of $23.00 and $24.00, respectively. OptimizeRx reported strong quarterly earnings, beating estimates with $0.20 EPS and $26.07 million in revenue. The stock has a consensus rating of "Moderate Buy" and an average price target of $16.88. Insider activity and hedge fund investments indicate confidence in the company's future performance.</p>

Wall Street Zen Upgrades OptimizeRx (NASDAQ:OPRX) to "Strong-Buy"